Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The **Omicron Inactivated COVID-19 Vaccine (Vero Cell)** is an inactivated vaccine developed to protect against COVID-19 caused by the Omicron variant of SARS-CoV-2. It uses whole virions of the Omicron strain propagated in Vero cells—a continuous cell line derived from African green monkey kidney cells—then inactivated (typically with beta-propiolactone or formaldehyde) to preserve key antigens while eliminating infectivity. The mechanism involves intramuscular injection to induce neutralizing antibodies and T-cell responses targeting the SARS-CoV-2 spike protein and other viral components, mimicking natural infection without causing disease. Primarily indicated for active immunization against symptomatic COVID-19 in adults and children, it was authorized in several countries including China, Indonesia, and others for booster use against Omicron subvariants.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Omicron Inactivated COVID-19 Vaccine (Vero Cell).